Navamayooran Thavanesan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Navamayooran Thavanesan has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Ganesh Vigneswaran
University of Southampton, United Kingdom
6 shared publications - Zoe S. Walters
Innovation for Translation Research Group, Faculty of Medicine, School of Cancer Sciences, University of Southampton, Southampton, UK
3 shared publications - Charlotte Parfitt
University Hospitals Southampton NHS Foundation Trust, United Kingdom
2 shared publications - Indu Bodala
School of Electronics and Computer Science, University of Southampton, Southampton, U.K.
2 shared publications Mohammad Naiseh
AFG College with the University of Aberdeen, Doha, Qatar
2 shared publications- Sarvapali Dyanand Ramchurn
University of Southampton, Southampton, United Kingdom
2 shared publications
Latest Publications
- 15 June 2026
- Published by Elsevier in Clinical Oncology
- Vol. 56, 104195
The Application of AI in Cancer MDT and its Legal Implication
- 15 June 2026
- Published by Elsevier in Clinical Oncology
- Vol. 56, 104195
The Application of AI in Cancer MDT and its Legal Implication
- Open Access
- 10 December 2025
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 200, 111373
Health care professionals’ perceptions of machine learning based clinical decision support systems for oesophageal cancer management
- 10 December 2025
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 200, 111373
Open AccessHealth care professionals’ perceptions of machine learning based clinical decision support systems for oesophageal cancer management
- Open Access
- 1 October 2025
- Published by Elsevier in eClinicalMedicine
- Vol. 89, 103527
Oesophageal cancer multi-disciplinary tool: a co-designed, externally validated, machine learning tool for oesophageal cancer decision making
- 1 October 2025
- Published by Elsevier in eClinicalMedicine
- Vol. 89, 103527
Open AccessOesophageal cancer multi-disciplinary tool: a co-designed, externally validated, machine learning tool for oesophageal cancer decision making
- Open Access
- 5 August 2024
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 180, 108978
Insights from explainable AI in oesophageal cancer team decisions
- 5 August 2024
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 180, 108978
Open AccessInsights from explainable AI in oesophageal cancer team decisions
- Open Access
- 12 July 2023
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 49 (11) , 106986
Machine learning to predict curative multidisciplinary team treatment decisions in oesophageal cancer
- 12 July 2023
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 49 (11) , 106986
Open AccessMachine learning to predict curative multidisciplinary team treatment decisions in oesophageal cancer
- Open Access
- 23 January 2023
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 27 (4) , 807-822
The Oesophageal Cancer Multidisciplinary Team: Can Machine Learning Assist Decision-Making?
- 23 January 2023
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 27 (4) , 807-822
Open AccessThe Oesophageal Cancer Multidisciplinary Team: Can Machine Learning Assist Decision-Making?
- 23 April 2021
- Published by Wiley in Anz Journal of Surgery
- Vol. 91 (10) , 2097-2105
Clinical factors associated with successful embolization of lower gastrointestinal bleeding
Aim: To develop a model of clinical factors that may predict: (1) technically and clinically successful embolization of a bleeding vessel at digital subtraction angiography (DSA) for lower gastrointestinal bleed (LGIB); (2) a negative DSA in the presence of positive CT‐mesenteric angiography (CTMA) for LGIB.Methods: A retrospective cohort study of all DSAs conducted with intent for embolization for acute LGIB over a 10‐year period was undertaken. Pre‐procedural and intra‐procedural clinical variables were evaluated using uni‐ and multi‐variate analysis.Results: One hundred and twenty‐three DSAs were evaluated. Technical success was 81% and clinical success 78% where DSA was positive. Technical success was associated with super‐selective approach, contrast extravasation on CT, haemoglobin drop, anatomical source and time from CT to DSA on univariate analysis. On multivariate analysis, time from CT to DSA was significant with a higher success probability within 120 min with different factors being salient depending on degree of delay. Clinical success was only associated with activated partial thromboplastin time (<27.5 s). A negative DSA was associated with anatomical source, haemodynamic stability, platelet count and time from CT to DSA on univariate analysis. The latter three remained so on multivariate analysis.Conclusion: A triaging approach to utilizing emergency DSA may be helpful. If prolonged delay between CT and DSA is anticipated, with haemodynamic stability and a near‐normal platelet count, the DSA may not be fruitful. Technical success may be more likely if DSA occurs within 120 min. Clinical success may be more likely if activated partial thromboplastin time is within normal range.
- 23 April 2021
- Published by Wiley in Anz Journal of Surgery
- Vol. 91 (10) , 2097-2105
Clinical factors associated with successful embolization of lower gastrointestinal bleeding
Aim: To develop a model of clinical factors that may predict: (1) technically and clinically successful embolization of a bleeding vessel at digital subtraction angiography (DSA) for lower gastrointestinal bleed (LGIB); (2) a negative DSA in the presence of positive CT‐mesenteric angiography (CTMA) for LGIB.Methods: A retrospective cohort study of all DSAs conducted with intent for embolization for acute LGIB over a 10‐year period was undertaken. Pre‐procedural and intra‐procedural clinical variables were evaluated using uni‐ and multi‐variate analysis.Results: One hundred and twenty‐three DSAs were evaluated. Technical success was 81% and clinical success 78% where DSA was positive. Technical success was associated with super‐selective approach, contrast extravasation on CT, haemoglobin drop, anatomical source and time from CT to DSA on univariate analysis. On multivariate analysis, time from CT to DSA was significant with a higher success probability within 120 min with different factors being salient depending on degree of delay. Clinical success was only associated with activated partial thromboplastin time (<27.5 s). A negative DSA was associated with anatomical source, haemodynamic stability, platelet count and time from CT to DSA on univariate analysis. The latter three remained so on multivariate analysis.Conclusion: A triaging approach to utilizing emergency DSA may be helpful. If prolonged delay between CT and DSA is anticipated, with haemodynamic stability and a near‐normal platelet count, the DSA may not be fruitful. Technical success may be more likely if DSA occurs within 120 min. Clinical success may be more likely if activated partial thromboplastin time is within normal range.
- 13 April 2018
- Published by Wiley in Colorectal Disease
- Vol. 20 (10) , 864-872
Management of patients with incurable colorectal cancer: a retrospective audit
Aims Counselling patients and their relatives about non‐curative management options in colorectal cancer is difficult because of a paucity of published data. This study aims to determine outcomes in patients unsuitable for curative surgery and the rates of subsequent surgical intervention. Methods Analysis of all colorectal cancers managed without curative surgery in a district general hospital from a prospectively maintained cancer registry between 2009 and 2016, as decided by multidisciplinary team (MDT). Primary outcomes were overall‐survival and secondary outcomes were subsequent intervention‐rates and impact of tumour stage. Results 183 patients out of 976 patients (18.8%) were identified. The median age at diagnosis was 81 yrs (Interquartile range (IQR) 71‐87). Overall median survival from diagnosis was 205 days (IQR 60‐532 days). One‐year mortality was 62.3%.Patients were classified into two groups depending on the reason for a non‐curable approach; Patient‐related (PR) or Disease‐related (DR). The difference in survival between PR (median 277 days, IQR 70‐593) and DR (median 179 days, IQR 51‐450) was 98 days (P = 0.023). Twenty‐four patients were alive at the end of the study period; 19 out of 91 cases in PR (20.8%) and 5 out of 92 cases in DR (5.4%). Overall intervention‐rates were 11.9%, with higher rates in DR group (P=0.005). Disease stage was not associated with subsequent surgical intervention between the two groups (P=0.392). Conclusion Life‐expectancy for non‐curatively managed patients within our unit was 6.8 months with 1 in 9 patients requiring subsequent surgical admission for palliation. This information may be useful when counselling patients with incurable colorectal malignancy.
- 13 April 2018
- Published by Wiley in Colorectal Disease
- Vol. 20 (10) , 864-872
Management of patients with incurable colorectal cancer: a retrospective audit
Aims Counselling patients and their relatives about non‐curative management options in colorectal cancer is difficult because of a paucity of published data. This study aims to determine outcomes in patients unsuitable for curative surgery and the rates of subsequent surgical intervention. Methods Analysis of all colorectal cancers managed without curative surgery in a district general hospital from a prospectively maintained cancer registry between 2009 and 2016, as decided by multidisciplinary team (MDT). Primary outcomes were overall‐survival and secondary outcomes were subsequent intervention‐rates and impact of tumour stage. Results 183 patients out of 976 patients (18.8%) were identified. The median age at diagnosis was 81 yrs (Interquartile range (IQR) 71‐87). Overall median survival from diagnosis was 205 days (IQR 60‐532 days). One‐year mortality was 62.3%.Patients were classified into two groups depending on the reason for a non‐curable approach; Patient‐related (PR) or Disease‐related (DR). The difference in survival between PR (median 277 days, IQR 70‐593) and DR (median 179 days, IQR 51‐450) was 98 days (P = 0.023). Twenty‐four patients were alive at the end of the study period; 19 out of 91 cases in PR (20.8%) and 5 out of 92 cases in DR (5.4%). Overall intervention‐rates were 11.9%, with higher rates in DR group (P=0.005). Disease stage was not associated with subsequent surgical intervention between the two groups (P=0.392). Conclusion Life‐expectancy for non‐curatively managed patients within our unit was 6.8 months with 1 in 9 patients requiring subsequent surgical admission for palliation. This information may be useful when counselling patients with incurable colorectal malignancy.
- Open Access
- 23 October 2014
- Published by S. Karger AG in Case Reports in Neurology
- Vol. 6 (3) , 232-237
Deep Brain Stimulation in Multiple System Atrophy Mimicking Idiopathic Parkinson's Disease
Deep brain stimulation (DBS) is approved for idiopathic Parkinson's disease (IPD) but has a poor evidence base in Parkinson-plus syndromes such as multiple system atrophy (MSA). We describe the clinical and neuropathological findings in a man who was initially diagnosed with IPD, in whom DBS was unsuccessful, and in whom MSA was unexpectedly diagnosed at a subsequent autopsy. This case report highlights that DBS is often unsuccessful in MSA and also demonstrates that MSA can masquerade as IPD, which may explain treatment failure in a small group of patients apparently suffering from Parkinson's disease. Additionally, it also presents a case with an unusually long duration of disease prior to death, comparable only to a handful of other cases in the literature.
- 23 October 2014
- Published by S. Karger AG in Case Reports in Neurology
- Vol. 6 (3) , 232-237
Open AccessDeep Brain Stimulation in Multiple System Atrophy Mimicking Idiopathic Parkinson's Disease
Deep brain stimulation (DBS) is approved for idiopathic Parkinson's disease (IPD) but has a poor evidence base in Parkinson-plus syndromes such as multiple system atrophy (MSA). We describe the clinical and neuropathological findings in a man who was initially diagnosed with IPD, in whom DBS was unsuccessful, and in whom MSA was unexpectedly diagnosed at a subsequent autopsy. This case report highlights that DBS is often unsuccessful in MSA and also demonstrates that MSA can masquerade as IPD, which may explain treatment failure in a small group of patients apparently suffering from Parkinson's disease. Additionally, it also presents a case with an unusually long duration of disease prior to death, comparable only to a handful of other cases in the literature.
- 3 August 2011
- Published by Cambridge University Press (CUP) in British Journal of Nutrition
- Vol. 106 (9) , 1297-1309
The putative effects of green tea on body fat: an evaluation of the evidence and a review of the potential mechanisms
The increase in the prevalence of obesity in recent years has prompted research into alternative methods of modulating body weight and body fat. The last decade has reflected this with a surge in studies investigating the potential of green tea as a natural agent of weight loss, with a view to confirming and elucidating the mechanisms underlying its effect on the body. Currently, it is widely believed that the polyphenolic components present in green tea have an anti-obesogenic effect on fat homeostasis, by increasing thermogenesis or reducing fat absorption among other ways. The data published to date, however, are inconsistent, with numerous putative modes of action suggested therein. While several unimodal mechanisms have been postulated, a more plausible explanation of the observed results might involve a multimodal approach. Such a mechanism is suggested here, involving simultaneous inhibition of the enzymes catechol-O-methyltransferase, acetyl-CoA carboxylase, fatty acid synthase and impeding absorption of fat via the gut. An evaluation of the available evidence supports a role of green tea in weight loss; however the extent of the effects obtained is still subject to debate, and requires more objective quantification in future research.
- 3 August 2011
- Published by Cambridge University Press (CUP) in British Journal of Nutrition
- Vol. 106 (9) , 1297-1309
The putative effects of green tea on body fat: an evaluation of the evidence and a review of the potential mechanisms
The increase in the prevalence of obesity in recent years has prompted research into alternative methods of modulating body weight and body fat. The last decade has reflected this with a surge in studies investigating the potential of green tea as a natural agent of weight loss, with a view to confirming and elucidating the mechanisms underlying its effect on the body. Currently, it is widely believed that the polyphenolic components present in green tea have an anti-obesogenic effect on fat homeostasis, by increasing thermogenesis or reducing fat absorption among other ways. The data published to date, however, are inconsistent, with numerous putative modes of action suggested therein. While several unimodal mechanisms have been postulated, a more plausible explanation of the observed results might involve a multimodal approach. Such a mechanism is suggested here, involving simultaneous inhibition of the enzymes catechol-O-methyltransferase, acetyl-CoA carboxylase, fatty acid synthase and impeding absorption of fat via the gut. An evaluation of the available evidence supports a role of green tea in weight loss; however the extent of the effects obtained is still subject to debate, and requires more objective quantification in future research.